Anita L. Nelson

ORCID: 0000-0002-7002-9613 · 6 papers in corpus
article 2022
·doi:10.1016/j.contraception.2022.04.002

ObjectivesTo describe ovulation inhibition and safety of daily oral ulipristal acetate (UPA) over 84 days.Study designThis multi-center phase 1 and/or 2 trial randomized participants to use oral ulipristal 10 mg or 5 mg daily or a 3 cycle r…

review 2015
Obstetrical & gynecological survey ·doi:10.1097/ogx.0000000000000155

Importance Heavy menstrual bleeding (HMB) is a common complaint among reproductive-aged women, which negatively affects their health as well as their social, professional, and family lives. Modern medical management usually provides effecti…

article 2013
·doi:10.3109/13625187.2013.780202

OBJECTIVE: To summarise all clinical data on the contraceptive efficacy and bleeding profile associated with an oestradiol valerate (E2V) and dienogest (DNG) [E2V/DNG] combined oral contraceptive (COC) derived from Phase III trials. METHODS…

article 2013
·doi:10.1089/jwh.2013.4320

BACKGROUND: This study investigated the efficacy and safety of a combined oral contraceptive (COC) containing estradiol valerate/dienogest (E2V/DNG). METHODS: This was a multicenter, noncomparative, 13-cycle (extended to 28 cycles) study co…

review 2007
·doi:10.1097/01.ogx.0000259228.70277.6f

An estimated 10%–30% of menstruating women experience menorrhagia at some time during their reproductive lives. Acute menorrhagia may present as an emergency requiring prompt medical or surgical intervention. Chronic menorrhagia affects a w…

review 2005
Treatments in endocrinology ·doi:10.2165/00024677-200504030-00002

Extended use of oral contraceptive (OC) pills can successfully suppress endometrial activity and prevent menstruation for several months. Given that missed menses in women not using hormonal contraception may be of medical concern, understa…